Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. La Vita Compounding Pharmacy, LLC
WARNING LETTER
•La Vita Compounding Pharmacy, LLC•June 8, 2018

La Vita Compounding Pharmacy, LLC – FDA Warning Letter, Jun 8, 2018

Record Details

The FDA inspected La Vita Compounding Pharmacy, LLC from June 4-8, 2018, identifying serious deficiencies in sterile drug production and failure to meet Section 503A conditions of the Federal Food, Drug, and Cosmetic Act (FDCA). The firm voluntarily ceased sterile production on June 22, 2018, and recalled all sterile drug products within expiry on June 25, 2018. Violations included compounding drug products using bulk substances (grape seed oil, green tea extract, hyaluronic acid, and dimethylaminoethanol bitartrate) that are not eligible for 503A exemptions, as they lack USP/NF monographs, are not FDA-approved drug components, and are not on the 503A bulks list. This renders these products unapproved new drugs, misbranded under 21 U.S.C. § 352(f)(1) due to inadequate directions for use, and subject to CGMP requirements. Additionally, drug products intended to be sterile were prepared under insanitary conditions, leading to adulteration under 21 U.S.C. § 351(a)(2)(A). FDA found the firm's proposed corrective actions, particularly regarding cleaning agents for non-sterile hazardous drug production equipment, inadequate, raising concerns about cross-contamination. FDA strongly recommends a comprehensive assessment of operations, including aseptic processing, with assistance from a third-party consultant. The firm must respond within fifteen working days, detailing corrective actions and preventive measures, or face potential legal action.

Company
La Vita Compounding Pharmacy, LLC
Inspection date
June 8, 2018
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations IV
Person
  • Steven E. Porter (Program Division Director)
View Company Profile

ID · 26b6da45-3eea-4c07-8124-cc0dfe6462eb

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 U.S.C. 353a21 U.S.C. 352(f)(1)21.U.S.C. 355(a)21 U.S.C. 331(k)FD&C Act 501(a)(2)(B)FD&C Act 502(f)(1)FD&C Act 505FD&C Act 501(a)(2)(A)

Full citation text and observation details available on the Dashboard.

Other documents for La Vita Compounding Pharmacy, LLC
  • 483 - 2020-03-11March 11, 2020
  • 483 - 2018-06-08June 8, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore La Vita Compounding Pharmacy, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.